Month: January 2024

MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) — Hut 8 Corp. (Nasdaq | TSX: HUT), (“Hut 8” or the “Company”) one of North America’s largest, most innovative digital asset mining pioneers and high performance computing infrastructure providers announces that it has received an approval and vesting order (the “Approval and Vesting Order“) from the Ontario Superior Court of Justice (Commercial List) in the context of the ongoing proceedings pursuant to the Companies’ Creditors Arrangement Act of Validus Power Corp. (“VPC“) and certain of its subsidiaries (collectively, the “Validus Entities“). Among other things, the Approval and Vesting Order approves the Company’s previously announced stalking horse bid transaction (the “Transaction“) to acquire four natural gas power plants...

First Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant Enrollment Progress Supports First Expected Clinical Data Readout in Second Half of 2024 European Clinical Trial Application (CTA) Submitted for BEAM-302; Trial Initiation in Alpha-1 Antitrypsin Deficiency Planned for First Half of 2024 Investigational New Drug (IND) Application for BEAM-301 On-track for First Half of 2024 Cash Runway Expected to Support Operating Plans into 2027 CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported progress across the company’s hematology and genetic disease portfolios and provided updates on anticipated upcoming milestones. “Our...

Iopofosine tested in heavily pretreated multi-class refractory population with a median of four prior therapies and achieves 75.6% Overall Response Rate; 61% Major Response Rate (95% CI, 44.5%, 75.8%); 100% Disease Control Rate exceeding protocol statistical hurdle of 20% Median Duration of Response not yet reached with a median of 8 months follow up Data continues to mature, anticipate increase in response rates and durationFLORHAM PARK, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced data from its CLOVER WaM pivotal study, evaluating iopofosine I 131, a potential first-in-class, targeted radiotherapy candidate for the treatment of...

– Industry-leading PK Activator Franchise Has Demonstrated Clinical Efficacy in Four Hematological Diseases, Including New Positive Phase 3 Data in Non-Transfusion-Dependent Thalassemia – – Company Expects Four Additional Phase 3 Readouts by the End of 2025, with Potential FDA Approvals in Thalassemia in 2025 and Sickle Cell Disease in 2026 – – Strong Cash Position Expected to Support Completion of Ongoing Programs and Disciplined Pipeline Expansion at Least into 2026 – CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced its anticipated 2024 milestones and value-driving catalysts through 2026 that support the company’s mission to transform patient outcomes in rare diseases. Agios will...

Company To Host Meetings at 26th Annual ICR Conference SYRACUSE, N.Y., Jan. 08, 2024 (GLOBE NEWSWIRE) — Carrols Restaurant Group, Inc. (“Carrols” or the “Company”) (Nasdaq: TAST), the largest BURGER KING® franchisee in the United States, today reported its preliminary sales results for the fourth quarter and full year 2023. Preliminary sales results for the Fourth Quarter of 2023 versus the Fourth Quarter of 2022 include:Total restaurant sales increased 5.7% to $470.4 million compared to $445.1 million in the fourth quarter of 2022; Comparable restaurant sales for the Company’s Burger King® restaurants increased 7.2%; and Comparable restaurant sales for the Company’s Popeyes® restaurants increased 7.6%.Preliminary sales results for the Full Year 2023 versus the Full Year 2022 include:Total restaurant sales increased 8.4%...

Durable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up period without need for lymphodepleting chemotherapy Descartes-08 observed to be well tolerated following administration in outpatient setting Publication is in peer review and available on the preprint server, medRxiv Topline data from Phase 2b placebo-controlled study continues to be expected in mid-2024 GAITHERSBURG, Md., Jan. 08, 2024 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC), (“the Company”) a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced positive twelve-month follow-up data from its Phase 2a trial of Descartes-08 in patients with generalized myasthenia gravis (MG), a chronic autoimmune disorder...

Admirals Group AS has announced a change to its supervisory and management board structure.  According to the Company’s general meeting of shareholders’ decision, Anton Tikhomirov, the member of Admiral Group AS’ supervisory board, was recalled as of January 3, 2024. By decision of the Supervisory Board he was appointed member of management board of Admirals Group AS starting from January 4, 2024. Anton Tikhomirov has been active in the industry since 1999 and has a managerial background in a financial brokerage. He joined Admirals in 2012 as he was first appointed to the Supervisory Board of Admiral Markets AS and later, in 2016, to the Supervisory Board of Admirals Group AS. He has been developing Admirals’ business activity in Spain and Latin America assuming later the responsibilities of the supervision of the regional structure. There...

– Initial Data from the Ongoing Phase 2 Trial in Combination with the Antibody-Drug Conjugate (ADC) Sacituzumab Govitecan (SG) Suggest a Potentially Meaningful Improvement in Overall Survival (OS) for Patients Receiving Trilaciclib – – COSELA® (trilaciclib) Vial Volume Growth Accelerated in the Fourth Quarter of 2023 with 19% Growth Over Prior Quarter – – Interim OS Analysis of Pivotal 1L Triple Negative Breast Cancer (TNBC) for Trilaciclib is Expected in the First Quarter of 2024 – – Cash Runway Expected into 2025 – RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced new clinical, commercial and corporate updates, including encouraging preliminary overall survival (OS) data from...

SAN MATEO, Calif. and SINGAPORE, Jan. 08, 2024 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (NASDAQ: ASLN) (“ASLAN” or the “Company”), announced today that on January 5, 2024, it received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the US$1.00 minimum bid price requirement under the Nasdaq Listing Rules (the “Listing Rules”). Based on the closing bid price of the Company’s listed securities for the 30 consecutive business days ended January 4, 2024, the Company has not met the minimum bid price requirement set forth in Listing Rule 5550(a)(2) during that period. The Notice is only a notification of deficiency and has no immediate effect on the...

RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) — Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient, provided a preliminary 2023 year-end corporate update. 2023 Full Year HighlightsOver 3,550 procedures were performed globally, representing 14% growth compared to 2022 In 2023, eight Senhance Surgical Programs were initiated, which is in line with guidance of 8-10 systems The Company had unaudited cash, cash equivalents and short-term investments, excluding restricted cash of approximately $21.0 million on December 31, 2023 Full year 2023 unaudited revenue is expected to be approximately $8.2 – $8.8 millionFourth Quarter HighlightsOver 835 procedures were performed globally using the Senhance® Surgical System Five Senhance...